Glenmark settles patent row

Glenmark Pharmaceuticals yesterday said its unit settled a legal row with riva GlaxoSmithKline over patent actions on doses of atovaquone and proguanil hydrochloride, the generic version of GSK’s Malarone malaria treatment tablets. Under terms of the settlement, Glenmark Generics would be able to market and distribute the generic version of Malarone tablets under a royalty-bearing license from GSK in the third quarter of calendar year 2011, or earlier in certain circumstances, it said in a statement. Malarone had sales of $56m (£36m) in the calendar year 2009 in the US market, it said.